文献速递肝病

失代偿期肝硬化的疾病修饰药物:从药物重定位到新药研发

The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery.
PubMed 文献 · J Hepatol · 2021-01-01

失代偿期肝硬化目前以针对特定并发症的靶向策略管理,而疾病修饰药物应全局性改善疾病进程。本文提出疾病修饰药物需在硬终点随机临床试验中显示明确获益,并综述白蛋白、他汀类、难吸收口服抗生素等重定位候选药物及新药研发方向。

要点

  • 疾病修饰药物需在硬终点随机试验中证实对疾病进程的明确获益
  • 病因治疗可延缓失代偿进展甚至诱导代偿逆转
  • 白蛋白、他汀类、难吸收口服抗生素是正在大型随机试验中评估的候选药物

核心结论

  • 失代偿期肝硬化存在疾病修饰药物的未满足临床需求,需能拮抗门脉高压、肠道易位、循环功能障碍、全身炎症和免疫功能障碍等关键病理生理机制。
  • 病因治疗通过消除肝硬化根本原因仍可影响失代偿病程,延缓进展甚至诱导代偿状态逆转。
  • 近年代谢重定位的「老药」如人白蛋白、他汀类和难吸收口服抗生素提供了少数候选药物,正在大型随机临床试验中进一步评估。

研究设计与样本

  • 本文为综述,检索范围原文未报告。

主要发现

  • 疾病修饰药物需在精心设计且样本量充足的随机临床试验中,以硬终点(即患者生存)证实对疾病进程的明确获益。
  • 这些试验还需明确目标人群、剂量与给药时机、指导治疗的因素、临时或永久停药规则、向日常临床实践的可推广性、成本效益和全球可及性。
  • 人白蛋白、他汀类和难吸收口服抗生素作为重定位候选药物正在大型随机临床试验中进一步评估。
  • 预计未来十年通过系统重定位现有药物和开发目前处于临床前或早期临床测试的新分子,将识别新的疾病修饰药物。

关键数值与推荐

  • 疾病修饰药物定义需在硬终点(患者生存)随机临床试验中显示明确获益。
  • 试验需定义目标人群、剂量、给药时机、治疗指导因素、停药规则、可推广性、成本效益和全球可及性。

临床怎么用

  • 失代偿期肝硬化当前管理仍以预防或治疗特定并发症的靶向策略为主。
  • 病因治疗应作为影响失代偿病程的基础措施。
  • 白蛋白、他汀类和难吸收口服抗生素等候选药物需等待大型随机临床试验结果后再用于疾病修饰目的。

局限性

  • 原文未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with decompensated cirrhosis are currently managed through targeted strategies aimed at preventing or treating specific complications. In contrast, a disease-modifying agent should, by definition, be aimed at globally addressing 'decompensated cirrhosis'. To be defined as a disease-modifying agent in decompensated cirrhosis, interventions need to demonstrate an unequivocal benefit on the course of disease in well-designed and adequately powered randomised clinical trials with hard endpoints (i.e. patient survival). These trials also need to define the target population, dosage and timing of administration, factors guiding treatment, temporary or permanent stopping rules, transferability to daily clinical practice, cost-effectiveness, and global treatment access. By eliminating the underlying cause of cirrhosis, aetiologic treatments can still influence the course of decompensated disease by halting or slowing down disease progression or even inducing reversion to the compensated state. In contrast, there remains an unmet clinical need for disease-modifying agents which can antagonise key pathophysiological mechanisms of decompensated cirrhosis, such as portal hypertension, gut translocation, circulatory dysfunction, systemic inflammation, and immunological dysfunction. However, in the last few years, the repurposing of "old drugs" that have already been prescribed for more limited indications in hepatology or for other diseases has provided a few candidates, including human albumin, statins, and poorly absorbable oral antibiotics, which are under further evaluation in large-scale randomised clinical trials. New disease-modifying agents are also expected to be identified in the next decade through the systematic repurposing of existing drugs and the development of novel molecules which are currently undergoing pre-clinical or early clinical testing.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Caraceni P, Abraldes JG, Ginès P, et al. The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery. J Hepatol. 2021. PMID: 34039483. doi:10.1016/j.jhep.2021.01.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。